Ann: Continued Use of ResAppDx at COVID-19 Respiratory Clinic, page-64

Completely agree with your sentiment.

Having worked in ICT with public health for a number of years, it takes a long time to get government to make decisions, particularly around new technologies and ways of working.

The value in this agreement continuing, is not the dollars in the door through licensing fees, but the evidence of the clinical utility and the clinical credibility, which will be worth much more in the long run.

This is sewing the seeds for widespread use in primary and tertiary healthcare settings across the country.